CHRS, US19249H1032

Coherus Oncology schedules October 28 webcast for Coherus Oncology stock

Published on 10/17/2026 at 19:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market cap hit USD 153.0 million on October 16, 2026. Coherus Oncology stock cost USD 0.99 on October 16, 2026, down 7.48 percent on Nasdaq.

Scheduled Data and Valuation

Coherus Oncology will host an October 28, 2026 webcast on interim Tagmokitug data.
Market capitalization stood at USD 153.0 million on October 16, 2026.
Coherus Oncology stock cost USD 0.99 on October 16, 2026 at 4:00 p.m. ET, down 7.48 percent versus the Nasdaq prior close.
The trailing price-to-earnings ratio was minus 0.97 on October 16, 2026.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology has scheduled an October 28, 2026 webcast to disclose interim Tagmokitug clinical data, according to Coherus Oncology. Coherus Oncology stock cost USD 0.99 on October 16, 2026 at 4:00 p.m. ET, down 7.48 percent versus the Nasdaq prior close of USD 1.07.

What comes on October 28?

The company has set the webcast for 4:30 p.m. EDT to disclose interim data on Tagmokitug, a Phase 1b antibody candidate targeting CCR8 in patients with advanced solid tumors. The investor-relations page also identifies Casdozokitug as a Phase 2 candidate targeting IL-27 in hepatocellular carcinoma.

The price remains near its low

The October 16 closing price stood 2.06 percent above the 52-week low of USD 0.97 and 62.21 percent below the high of USD 2.62. Trading volume reached 938,496 shares, 23.72 percent below the average volume of 1,230,300 shares.

Valuation and the next date

Market capitalization was USD 153.0 million on October 16, 2026, while the trailing price-to-earnings ratio was minus 0.97. The October 28 webcast is the next scheduled company event and will focus on clinical data rather than a financial update.

Comparison with peers

Coherus Oncology (Nasdaq, USD): minus 7.48 percent, P/E minus 0.97, market capitalization USD 153.0 million
Alkermes (Nasdaq, USD): plus 2.79 percent, P/E 107.62, market capitalization USD 6.9 billion
Iovance Biotherapeutics (Nasdaq, USD): minus 7.47 percent, P/E minus 18.66, market capitalization USD 6.2 billion

Stock stays near the yearly low

The October 16 close placed Coherus Oncology 0.02 USD above its yearly low, while its market value remained below the billion-dollar level. The October 28 webcast gives the next dated point for assessing progress in the clinical pipeline.